The previously unreported double-blind, placebo-controlled exploratory Phase 2A study was designed to evaluate the efficacy, safety, and tolerability of intranasal administration of PH284 in ...

Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...

January 14, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results ...

The second phase of Pittsburgh Regional Transit’s Unversity Line project has started. On Monday evening, crews began ...

Kuwait Oil Company (KOC) is expected to announce the results of drilling and exploration operations in Jazza offshore field ...